Evidence map›Paper›PMID 33219093›Full record

ArticleJournal for immunotherapy of cancer2020

Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer.

Paul Johannet, Amelia Sawyers, Yingzhi Qian, Samuel Kozloff, Nicholas Gulati, Douglas Donnelly, Judy Zhong, Iman Osman

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 67 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 5 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 5 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Prognostic value of SUVTranslational lung cancer research · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Prognostic utility of the CALLY index in metastatic melanoma: building a nomogram for Patients on Anti-PD-1 therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Paul JohannetMedicine, New York University School of Medicine, New York City, New York, USA.ORCID 0000-0002-9264-8327
Amelia SawyersDermatology, New York University School of Medicine, New York City, New York, USA.
Yingzhi QianPopulation Health, New York University School of Medicine, New York City, New York, USA.
Samuel KozloffMedicine, New York University School of Medicine, New York City, New York, USA.
Nicholas GulatiDermatology, New York University School of Medicine, New York City, New York, USA.
Douglas DonnellyDermatology, New York University School of Medicine, New York City, New York, USA.
Judy ZhongPopulation Health, New York University School of Medicine, New York City, New York, USA.
Iman OsmanDermatology, New York University School of Medicine, New York City, New York, USA iman.osman@nyulangone.org.
New York University · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIRCHHOFF, TOMAS · 2019 to 2025
$12.5M
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibitionR01CA231295 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSMAN, IMAN, WEBER, JEFFREY S · 2018 to 2022
$2.4M
NCI NIH HHS P30 CA016087NCI NIH HHS P50 CA225450NCI NIH HHS R01 CA231295
6 · The paper itself

Abstract

backgroundRecent research suggests that baseline body mass index (BMI) is associated with response to immunotherapy. In this study, we test the hypothesis that worsening nutritional status prior to the start of immunotherapy, rather than baseline BMI, negatively impacts immunotherapy response.

methodsWe studied 629 patients with advanced cancer who received immune checkpoint blockade at New York University. Patients had melanoma (n=268), lung cancer (n=128) or other primary malignancies (n=233). We tested the association between BMI changes prior to the start of treatment, baseline prognostic nutritional index (PNI), baseline BMI category and multiple clinical end points including best overall response (BOR), objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).

resultsDecreasing pretreatment BMI and low PNI were associated with worse BOR (p

conclusionStandard of care measures of worsening nutritional status more accurately associate with immunotherapy outcomes than static measurements of BMI. Future studies should focus on determining whether optimizing pretreatment nutritional status, a modifiable variable, leads to improvement in immunotherapy response.

Indexed as

AdultAgedAged, 80 and overBody Mass IndexFemaleHumansImmunotherapyMaleMiddle AgedNeoplasmsNutrition AssessmentPrognosisTreatment OutcomeYoung Adultimmunotherapy

Identifiers

PMID33219093
PMCPMC7682457
OpenAlexW3100580549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.